46.93
1.79 (3.97%)
| Penutupan Terdahulu | 45.14 |
| Buka | 45.14 |
| Jumlah Dagangan | 482,438 |
| Purata Dagangan (3B) | 490,518 |
| Modal Pasaran | 2,155,694,336 |
| Harga / Pendapatan (P/E TTM) | 109.14 |
| Harga / Jualan (P/S) | 1.83 |
| Harga / Buku (P/B) | 1.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | 1.87% |
| Margin Operasi (TTM) | -4.31% |
| EPS Cair (TTM) | 0.460 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 55.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.69% |
| Nisbah Semasa (MRQ) | 1.38 |
| Aliran Tunai Operasi (OCF TTM) | 163.69 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 122.12 M |
| Pulangan Atas Aset (ROA TTM) | 0.35% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.73% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Menurun |
| Health Information Services (Global) | Menurun | Menurun | |
| Stok | Omnicell, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.78% |
| % Dimiliki oleh Institusi | 104.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Keybanc, 27.85%) | Beli |
| 60.00 (Benchmark, 27.85%) | Beli | |
| Median | 60.00 (27.85%) | |
| Rendah | 52.00 (Wells Fargo, 10.80%) | Beli |
| Purata | 57.33 (22.16%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 48.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Benchmark | 02 Feb 2026 | 60.00 (27.85%) | Beli | 48.70 |
| 09 Dec 2025 | 50.00 (6.54%) | Beli | 43.49 | |
| Keybanc | 08 Jan 2026 | 60.00 (27.85%) | Beli | 50.59 |
| Wells Fargo | 05 Jan 2026 | 52.00 (10.80%) | Beli | 46.93 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 |
| 08 Dec 2025 | Pengumuman | Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management |
| 01 Dec 2025 | Pengumuman | Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show |
| 20 Nov 2025 | Pengumuman | Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Pengumuman | Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |